ulcerative colitis Archives -

Open communication helps ulcerative colitis patients through COVID-19

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, inflammatory bowel disease, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

https://pharmaphorum.com/news/pfizers-arena-buyout-looks-canny-as-etrasimod-aces-phase-3-trials/

News/ News/ R&D

Second trial opens door for Lilly’s mirikizumab in ulcerative colitis

Phil Taylor Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis 0 Comment

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody

Second trial opens door for Lilly’s mirikizumab in ulcerative colitis

https://pharmaphorum.com/news/second-trial-opens-door-for-lillys-mirikizumab-in-ulcerative-colitis/

News/ News/ R&D

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

Phil Taylor Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia 0 Comment

It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

https://pharmaphorum.com/news/etrasimod-data-suggests-pfizers-6-7bn-gamble-on-arena-will-pay-off/

News/ News/ R&D

Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

Phil Taylor Eli Lilly, inflammatory bowel disease, mirikizumab, ulcerative colitis 0 Comment

Eli Lilly has reported phase 3 results with its ulcerative colitis challenger mirikizumab, as it waits for the

Lilly unveils mirikizumab data in ulcerative colitis as it preps filings

https://pharmaphorum.com/news/lilly-unveils-mirikizumab-data-in-ulcerative-colitis-as-it-preps-filings/

News/ News/ R&D

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

https://pharmaphorum.com/news/flush-with-covid-cash-pfizer-tables-6-7bn-bid-for-arena/

News/ News/ R&D

Failed IBD trial dents confidence in BMS’ deucravacitinib

Phil Taylor Amgen, Bristol-Myers Squibb, deucravacitinib, inflammatory bowel disease, Otezla, ulcerative colitis 0 Comment

Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD)

Failed IBD trial dents confidence in BMS’ deucravacitinib

https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/

News/ News/ R&D

Trials leave Galapagos’ SIK programme looking under the weather

Phil Taylor Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis 0 Comment

Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound

Trials leave Galapagos’ SIK programme looking under the weather

https://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/

News/ News/ R&D

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

Phil Taylor Crohn's disease, dermatology, Eli Lilly, gastrointestinal, Immunology and inflammation, mirikizumab, psoriasis, ulcerative colitis 0 Comment

Eli Lilly has walked away from a major indication for its blockbuster hopeful mirikizumab, shelving plans to file

Crowded psoriasis market cuts Lilly’s mirikizumab ambitions

https://pharmaphorum.com/news/crowded-psoriasis-market-cuts-lillys-mirikizumab-ambitions/

News/ News/ R&D

Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial

Richard Staines Eli Lilly, inflammatory diseases, mirikizumab, ulcerative colitis 0 Comment

A phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target –

Lilly’s mirikuzumab hits target in phase 3 ulcerative colitis trial

https://pharmaphorum.com/news/lillys-mirikuzumab-hits-target-in-phase-3-ulcerative-colitis-trial/

Trending

ulcerative colitis

Login